Journal of the Neurological Sciences
Volume 222, Issue 1 , Pages 65-73 , 15 July 2004

Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b

Received 3 October 2003 ,Revised 9 April 2004 ,Accepted 12 April 2004.

References 

  1. Steinman L, Miller A, Bernard CC, Oksenberg JR. The epigenetics of multiple sclerosis: clues to etiology and a rationale for immune therapy. Annu. Rev. Neurosci. 1994;17:247–265
  2. Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr. Opin. Neurol. 1999;12:309–321
  3. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998;51:682–689
  4. Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology. 1995;45:2173–2177
  5. Khan OA, Hebel JR. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis. Ann. Neurol. 1998;44:138–139
  6. Furlan R, Bergami A, Lang R, Brambilla E, Franciotta D, Martinelli V, et al.  Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J. Neuroimmunol. 2000;111:86–92
  7. Karp CL, van Boxel-Dezaire AH, Byrnes AA, Nagelkerken L. Interferon-β in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?. Curr. Opin. Neurol. 2001;14:361–368
  8. Kira J, Kanai T, Nishimura Y, Yamasaki K, Matsushita S, Kawano Y, et al.  Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann. Neurol. 1996;40:569–574
  9. Yamasaki K, Horiuchi I, Minohara M, Kawano Y, Ohyagi Y, Yamada T, et al.  HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain. 1999;122:1689–1696
  10. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001;50:121–127
  11. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452
  12. Ochi H, Wu XM, Osoegawa M, Horiuchi I, Minohara M, Murai H, et al.  Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. J. Neuroimmunol. 2001;119:297–305
  13. Wandinger KP, Sturzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, et al.  Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 2001;50:349–357
  14. Gniadek P, Aktas O, Wandinger K-P, Bellmann-Strobl J, Wengert O, Weber A, et al.  Systemic IFN-β treatment induces apoptosis of peripheral immune cells in MS patients. J. Neuroimmunol. 2003;137:187–196
  15. Ahn J, Feng X, Patel N, Dhawan N, Reder AT. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis. Front. Biosci. 2004;9:1547–1555
  16. Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 2002;25:313–319
  17. Ochi H, Osoegawa M, Wu XM, Minohara M, Horiuchi I, Murai H, et al.  Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J. Neurol. Sci. 2002;201:45–51
  18. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington C, et al.  Late complications of immune deviation therapy in a nonhuman primate. Science. 1996;274:2054–2057
  19. Lafaille JJ, van de Keere F, Hsu AL, Baron JL, Haas W, Raine CS, et al.  Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 1997;186:307–312
  20. de Vries JE. Molecular and biological characteristics of interleukin-13. Chem. Immunol. 1996;63:204–218
  21. de la Barrera S, Finiasz M, Fink S, Ilarregui J, Alemán M, Olivares L, et al.  NK cells modulate the cytotoxic activity generated by Mycobacterium leprae-hsp65 in leprosy patients: role of IL-18 and IL-13. Clin. Exp. Immunol. 2004;135:105–113
  22. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997;186:1677–1687
  23. Baxter AG, Smyth MJ. The role of NK cells in autoimmune disease. Autoimmunity. 2002;35:1–14
  24. Kastrukoff LF, Lau A, Wee R, Zecchini D, White R, Paty DW. Clinical relapses of multiple sclerosis are associated with ‘novel’ valleys in natural killer cell functional activity. J. Neuroimmunol. 2003;145:103–114
  25. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today. 1994;15:19–26
  26. Cash E, Minty A, Ferrara P, Caput D, Fradelizi D, Rott O. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J. Immunol. 1994;153:4258–4267
  27. Szczepanik AM, Funes S, Petko W, Ringheim GE. IL-4, IL-10 and IL-13 modulate A beta(1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol. 2001;113:49–62
  28. Sironi M, Sciacca FL, Matteucci C, Conni M, Vecchi A, Bernasconi S, et al.  Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood. 1994;84:1913–1921
  29. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J. Immunol. 1995;154:799–803
  30. Zettl UK, Mix E, Zielasek J, Stangel M, Hartung HP, Gold R. Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell. Immunol. 1997;178:1–8
  31. Bogdan C. The multiplex function of nitric oxide in (auto)immunity. J. Exp. Med. 1998;187:1361–1365
  32. Willenborg DO, Fordham SA, Staykova MA, Ramshaw IA, Cowden WB. IFN-γ is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J. Immunol. 1999;163:5278–5286
  33. van der Veen RC, Dietlin TA, Dixon Gray J, Gilmore W. Macrophage-derived nitric oxide inhibits the proliferation of activated T helper cells and is induced during antigenic stimulation of resting T cells. Cell. Immunol. 2000;199:43–49
  34. Nakashima I, Fujihara K, Misu T, Fujimori J, Sato S, Takase S, et al.  A comparative study of Japanese multiple sclerosis patients with and without oligoclonal IgG bands. Mult. Scler. 2002;8:459–462
  35. Horiuchi I, Kawano Y, Yamasaki K, Minohara M, Furue M, Taniwaki T, et al.  Th1 dominance in HAM/TSP and the optico-spinal form of multiple sclerosis versus Th2 dominance in mite antigen-specific IgE myelitis. J. Neurol. Sci. 2000;172:17–24
  36. Wu XM, Osoegawa M, Yamasaki K, Kawano Y, Ochi H, Horiuchi I, et al.  Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. J. Neurol. Sci. 2000;177:24–31

PII: S0022-510X(04)00108-X

doi: 10.1016/j.jns.2004.04.012

Journal of the Neurological Sciences
Volume 222, Issue 1 , Pages 65-73 , 15 July 2004

Article Tools

* Image Usage & Resolution